Population pharmacokinetics of free flucloxacillin in patients treated with oral flucloxacillin plus probenecid.
Philip George DrennanJared K GreenSharon J GardinerSarah C L MetcalfCarl M J KirkpatrickRichard J EvertsMei ZhangStephen T ChambersPublished in: British journal of clinical pharmacology (2021)
The simulation results reported can be used to identify dose regimens that optimise flucloxacillin exposure according to eGFR and FFM. Patients with higher FFM and eGFR may require the addition of probenecid and 6-hourly dosing to achieve PK/PD targets. The regimen was well-tolerated, suggesting a potential for further evaluation in controlled clinical trials to establish efficacy.